LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Open

BrancheGesundheitswesen

91.21 -0.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

90.5

Max

93.23

Schlüsselkennzahlen
By Trading Economics
Einkommen	-8.1M -56M
Verkäufe	2.9M 60M
EPS	-0.83
Gewinnspanne	-92.559
Angestellte	414
EBITDA	-9.7M -52M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+49.61% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	301M 6.2B
Vorheriger Eröffnungskurs	91.4
Vorheriger Schlusskurs	91.21

Nachrichtenstimmung

By Acuity

68%

32%

301 / 344 Ranking in Healthcare

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Mai 2026, 22:47 UTC

Ergebnisse

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. Mai 2026, 20:45 UTC

Ergebnisse

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. Mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. Mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. Mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. Mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. Mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. Mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. Mai 2026, 22:37 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. Mai 2026, 22:04 UTC

Akquisitionen, Fusionen, Übernahmen

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. Mai 2026, 22:04 UTC

Akquisitionen, Fusionen, Übernahmen

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. Mai 2026, 21:12 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. Mai 2026, 21:00 UTC

Ergebnisse

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. Mai 2026, 20:57 UTC

Ergebnisse

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. Mai 2026, 20:55 UTC

Ergebnisse

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. Mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. Mai 2026, 20:48 UTC

Heiße Aktien

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. Mai 2026, 20:34 UTC

Ergebnisse

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. Mai 2026, 20:31 UTC

Ergebnisse

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. Mai 2026, 20:28 UTC

Ergebnisse

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. Mai 2026, 20:26 UTC

Ergebnisse

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. Mai 2026, 20:20 UTC

Ergebnisse

Costco 3Q Membership Fees $1.37B

28. Mai 2026, 20:20 UTC

Ergebnisse

Costco 3Q Net Sales $69.15B

28. Mai 2026, 20:19 UTC

Ergebnisse

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. Mai 2026, 20:19 UTC

Ergebnisse

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. Mai 2026, 20:17 UTC

Ergebnisse

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. Mai 2026, 20:17 UTC

Ergebnisse

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

49.61% Vorteil

12-Monats-Prognose

Durchschnitt 136.77 USD 49.61%

Hoch 158 USD

Tief 105 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

301 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.